Toggle Main Menu Toggle Search

Open Access padlockePrints

Targeting the Hippo pathway in prostate cancer: What’s new?

Lookup NU author(s): Dr Kelly Coffey



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2021 by the author. Licensee MDPI, Basel, Switzerland. Identifying novel therapeutic targets for the treatment of prostate cancer (PC) remains a key area of research. With the emergence of resistance to androgen receptor (AR)-targeting therapies, other signalling pathways which crosstalk with AR signalling are important. Over recent years, evidence has accumulated for targeting the Hippo signalling pathway. Discovered in Drosophila melanogasta, the Hippo pathway plays a role in the regulation of organ size, proliferation, migration and invasion. In response to a variety of stimuli, including cell–cell contact, nutrients and stress, a kinase cascade is activated, which includes STK4/3 and LATS1/2 to inhibit the effector proteins YAP and its paralogue TAZ. Transcription by their partner transcription factors is inhibited by modulation of YAP/TAZ cellular localisation and protein turnover. Trnascriptional enhanced associate domain (TEAD) transcription factors are their classical transcriptional partner but other transcription factors, including the AR, have been shown to be modulated by YAP/TAZ. In PC, this pathway can be dysregulated by a number of mechanisms, making it attractive for therapeutic intervention. This review looks at each component of the pathway with a focus on findings from the last year and discusses what knowledge can be applied to the field of PC.

Publication metadata

Author(s): Coffey K

Publication type: Review

Publication status: Published

Journal: Cancers

Year: 2021

Volume: 13

Issue: 4

Online publication date: 04/02/2021

Acceptance date: 20/01/2021

ISSN (electronic): 2072-6694

Publisher: MDPI AG


DOI: 10.3390/cancers13040611